United Therapeutics Hits Enrollment Milestone in PPF Trial for Tyvaso
Event summary
- United Therapeutics completed enrollment of 754 patients in the TETON-PPF study evaluating Tyvaso for progressive pulmonary fibrosis (PPF).
- The phase 3 trial is a multinational, randomized, double-blind, placebo-controlled study with topline data expected in late 2027.
- If successful, the study could support a supplemental New Drug Application (sNDA) to add PPF to Tyvaso’s labeled indications.
- United Therapeutics is also seeking priority review of an sNDA for Tyvaso in idiopathic pulmonary fibrosis (IPF), submitted in June 2026.
The big picture
United Therapeutics is expanding Tyvaso’s potential beyond pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) into PPF, a condition with limited treatment options. The rapid enrollment in TETON-PPF reflects both the unmet need in PPF and the company’s strategic push to leverage Tyvaso’s proven efficacy in related fibrotic diseases. Success in this trial could significantly broaden Tyvaso’s market and solidify United Therapeutics’ leadership in treating progressive fibrotic lung conditions.
What we're watching
- Regulatory Pathway
- Whether the FDA will grant priority review for the IPF sNDA and how quickly it may approve Tyvaso for PPF if the TETON-PPF trial succeeds.
- Clinical Efficacy
- The extent to which Tyvaso’s mechanism in IPF translates to PPF, given the similarities in fibrosis mechanisms.
- Market Opportunity
- The potential addressable market for Tyvaso in PPF, estimated at 200,000 patients in the U.S., and its revenue impact.
Related topics